Leerink Partners Remains Bullish on McKesson Corporation (MCK), Retains a $785 Price Target

McKesson Corporation (NYSE:MCK) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. On June 11, analyst Michael Cherny of Leerink Partners maintained a Buy rating on McKesson Corporation (NYSE:MCK), retaining the price target of $785.00. The analyst based the rating on the company’s recent operational strength, which led to an increase in its EPS guidance.

McKesson Corporation (NYSE:MCK) reported earnings per diluted share of $10.01 in fiscal Q4 2025, reflecting a growth of $3.99. Adjusted earnings per diluted share in the quarter reached $10.12, with a notable growth of 64%.

The company provided optimistic guidance for fiscal 2026, with adjusted earnings per diluted share expected to be in the range of $36.75 to $37.55, indicating forecasted growth of 11% to 14% compared to the prior year.

The analyst viewed McKesson Corporation’s (NYSE:MCK) operational improvement across various segments as modestly positive, especially because it allows the company to mitigate concerns associated with unexpected tax issues that materialized in the previous fiscal year.

McKesson Corporation (NYSE:MCK) ranks seventh on our list of the best drug stocks to invest in now and distributes generic, branded, specialty, biosimilar, and over-the-counter pharmaceutical drugs through its US pharmaceutical segment. The company also operates through the Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International segments.

While we acknowledge the potential of MCK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.